SGMT

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is 29.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sagimet Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Sagimet Biosciences Inc. EPS for the last quarter amounts to -0.40 USD, decreased -11.11 % YoY.

Sagimet Biosciences Inc (SGMT) has 14 emplpoyees as of December 17 2025.

Today SGMT has the market capitalization of 196.76M USD.